Article

Forbes on 2018-12-03 15:32

GSK Buys Tesaro For $5 Billion In Dramatic Bet On Cancer Genetics

The deal is a dramatic bet that the London-based drug giant can see opportunities connected to the genetics of cancer drugs better than the stock ...

Clovis

Related news

NGSK buying cancer drugmaker Tesaro in $5.1 billion deal nypost.com
United Kingdom
Drugmaker GSK buys US cancer firm for $1.9 billion timesofmalta.com
Malta
WGSK acquiring oncology firm Tesaro in $5.1B deal, sells health drinks for $3.7B wraltechwire.com
Zebulon , Bangladesh , India
Dividends a worry at drugmakers Astra, GSK after dramatic week metro.us
China , islands , United Kingdom
WGSK invests $300M in genetics startup 23andMe for new medicine search wraltechwire.com
$300M DNA play: GSK to collaborate with 23andMe on genetics-driven drug discovery bizjournals.com
GSK/TESARO BrandVoice: Beyond The Clinic: The Commonality Between Living With Ovarian Cancer And Working As The Researcher Behind A Treatment Forbes
Watampone , Minneapolis , Massachusetts
HGSK Buys 10% of CureVac in Vaccine Tech Deal hamodia.com
Germany
MTesaro stock dives 7% after drug pricing snafu marketwatch.com
Clovis , The Street
GlaxoSmithKline to spend $5.1B on cancer drugmaker Tesaro Merced Sun-Star
Waltham
FGSK to boost cancer drugs pipeline with $5.1bn Tesaro purchase ft.com
Post-GSK purchase, Tesaro readies for cancer clash with Merck bizjournals.com
GSK taps new CEO bizjournals.com
Research Triangle Park
GSK Buys Novartis’s Stake in Health-Care Unit for $13 Billion wsj.com
BRichard Branson’s Next Frontier Is Human Genetics as His SPAC Buys 23andMe barrons.com